NCT00786851已完成2 期
Salvage Treatment With Lenalidomide and Dexamethaosne(LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 17
- 主要终点
- To explore the antitumor activity of the association of Len-Dex in term of overall (OR) and complete response (CR) in patients with relapsed/refractory MCL
研究概览
简要总结
This is a prospective, multicenter phase II trial designed to evaluate the safety and activity of the combination of Lenalidomide (Len) and Dexamethasone (Dex) in patients with relapsed/refractory mantle cell lymphoma (MCL).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of MCL
- •Understand and voluntarily sign an informed consent form;
- •Able to adhere to the study visit schedule and other protocol requirements;
- •Age ≥ 18;
- •Patients treated with at least one prior treatment regimen, not eligible for or relapsed after more intensive treatments (stem cell transplant);
- •Patients with refractory or relapsed disease;
- •Measurable and/or valuable disease;
- •Adequate haematological counts: ANC > 1.5 x 109/L and platelet count > 75 x 109/L unless due to bone marrow involvement by MCL;
- •Conjugated bilirubin up to 2 x ULN unless due to liver involvement by MCL;
- •Alkaline phosphatase and transaminases up to 2 x ULN unless due to liver involvement by MCL;
- •Creatinine clearance ≥ 50 ml/min;
- •HIV negativity;
- •HCV negativity;
- •HBV negativity or patients with HBcAb +, HbsAg -, HBs Ab+/- and anti HBV prophylaxis with lamivudine;
- •Non peripheral neuropathy or CNS disease;
- •Life expectancy > 6 months;
- •Performance status < 2 according to ECOG scale;Disease free of prior malignancies (a part MCL) with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast;
- •Written informed consent;
- •Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study. The two methods of reliable contraception must include one highly effective method (i.e. intrauterine device (IUD), hormonal [birth control pills, injections, or implants], tubal ligation, partner's vasectomy) and one additional effective (barrier) method (i.e. latex condom, diaphragm, cervical cap). FCBP must be referred to a qualified provider of contraceptive methods if needed;
排除标准
- •Patients who have received an experimental drug or used an experimental medical device within 4 weeks before the planned start of treatment. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study;
- •CNS disease (meningeal and/or brain involvement by lymphoma);
- •TVP in the last year;
- •History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances;
- •Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug);
- •Creatinine clearances < 50 ml/min;
- •HIV positivity;
- •HBV positivity with the exception of patients with HBVcAb +, HbsAg -, HBs Ab+/- in anti HBV prophilaxis with lamivudine;
- •Pregnant or lactating women;
- •Hypersensitivity reactions to previous thalidomide (if any);
- •Prior rash ≥ 3 while taking thalidomide (if any);
- •Active opportunistic infection;
- •Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent;
研究组 & 干预措施
1
Experimental
Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
干预措施: Lenalidomide and Dexametasone (Drug)
结局指标
主要结局
To explore the antitumor activity of the association of Len-Dex in term of overall (OR) and complete response (CR) in patients with relapsed/refractory MCL
时间窗: 3 years
次要结局
- To explore the safety profile;(2 years)
- To evaluate the clinical efficacy of Len-Dex in terms of response duration (RD) and overall survival (OS).(2 years)
- To explore the modification of tumoral neo-angiogenic biomarkers and the relationship with response to Len-Dex therapy;(2 years)
研究者
研究点 (17)
Loading locations...
相似试验
进行中（未招募）
2 期
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MMMyeloma, MultipleNCT04009109Alliance Foundation Trials, LLC.79
终止
1 期
Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisPDiffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma Grade III (FL III°)Mantle Cell Lymphoma (MCL), Blastoid VariantBurkitt Lymphoma (BL)Aggressive Marginal Zone Lymphoma (MZL)NCT02983097Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH34
已完成
2 期
Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell LymphomaDiffuse Large B-cell LymphomaNCT00799513IRCCS San Raffaele48
已完成
2 期
Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple MyelomaDS Stage I Plasma Cell MyelomaDS Stage II Plasma Cell MyelomaDS Stage III Plasma Cell MyelomaRefractory Plasma Cell MyelomaNCT00445692Fred Hutchinson Cancer Center32
进行中（未招募）
2 期
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary AmyloidosisRecurrent Primary AmyloidosisNCT03252600Barbara Ann Karmanos Cancer Institute53